Bank of Nova Scotia Invests $1.11 Million in Insulet Corporation $PODD

Bank of Nova Scotia acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 7,270 shares of the medical instruments supplier’s stock, valued at approximately $1,107,000.

Several other hedge funds also recently modified their holdings of PODD. Elevation Point Wealth Partners LLC acquired a new stake in Insulet during the second quarter valued at approximately $218,000. Commerce Bank purchased a new stake in Insulet in the 2nd quarter worth approximately $1,510,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Insulet during the second quarter valued at $127,000. Quantbot Technologies LP bought a new stake in shares of Insulet in the 2nd quarter valued at approximately $291,000. Finally, Evolve Private Wealth LLC acquired a new position in shares of Insulet during the 2nd quarter worth $523,000.

Insulet Price Performance

Shares of NASDAQ PODD opened at $143.38 on Thursday. The business’s 50 day moving average price is $154.52 and its two-hundred day moving average price is $182.09. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.94 billion, a PE ratio of 26.80, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.36% of the company’s stock.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Evercore set a $180.00 price objective on shares of Insulet in a report on Monday, July 6th. BTIG Research downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. UBS Group cut their target price on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Canaccord Genuity Group decreased their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, Jefferies Financial Group lowered their target price on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Fourteen research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Insulet has an average rating of “Hold” and an average price target of $195.40.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.